215 First Street
Eleven Biotherapeutics, Inc. is a preclinical-stage biopharmaceutical company with a proprietary protein engineering platform, called AMP-Rx, that it applies to the discovery and development of protein therapeutics to treat diseases of the eye. Eleven’s therapeutic approach is based on the role of cytokines in diseases of the eye, the Company’s understanding of the structural biology of cytokines and the Company’s ability to rationally design and engineer proteins to modulate the effects of cytokines. Cytokines are cell signaling molecules found in the body that can have important inflammatory effects.
Founder: Reza Dana, K. Christopher Garcia, Greg Verdine, Casey Weaver, K. Dane Wittrup
CEO: Abbie Celniker
CMO (Medical): Michael Goldstein
Please click here for Eleven Biotherapeutics.